Woman leaders in science talk mentoring, networking, work-life-balance: A TweetChat
Join the #WomenInScience TweetChat
9 November 2016, 13:00-14:00 (CET)
Women scientists have transformed biomedical research with their discoveries, and their leadership is needed to drive life sciences into the future. Still, women in science are underrepresented at senior levels of most research institutes. Their voices are essential in discussions about work-life balance, the need for mentorship to guide career development, and networking.
Join our panelists in discussing how to advance the careers of #WomenInScience.
Susan M. Gasser, PhD
Susan M. Gasser, PhD,
Director of the Friedrich Miescher Institute for Biomedical Research.
Prof. Susan M. Gasser is the director of the Friedrich Miescher Institute for Biomedical Research, a position she assumed in 2004. In parallel, she holds a professorship at the University of Basel. Before joining the FMI, Susan Gasser was Professor of Molecular Biology at the University of Geneva, and for the preceding 15 years, she led a research group at the Swiss Institute for Experimental Cancer Research in Epalinges/Lausanne, Switzerand. Trained in biology and biophysics at the University of Chicago, she obtained her PhD in Biochemistry at the University of Basel, having established an in vitro system for mitochondrial protein import. As a postdoctoral fellow, she identified topoisomerase II as a structural component of metaphase chromosomes and a role for AT rich sequences in long-range chromatin organization.
Susan Gasser's laboratory studies how nuclear organization impinges on mechanisms of repair and replication fork stability and on epigenetic inheritance of cell fate decisions. She exploits the genetics of model organisms in her studies, as well as quantitative live fluorescence imaging. She has authored more than 250 primary articles and reviews, and has received a number of awards for her work, including election to the Académie de France, EMBO and the Swiss Academy of Medical Sciences. She received the INSERM International Prize in 2011, the FEBS | EMBO Women in Science Award in 2012, the Otto Naegeli Award and Gregor Mendel Medal in 2006, and the Weizmann Institute Women in Science award in 2013, as well as an honorary doctorate from the University of Lausanne. She is a member of many scientific review panels for institutes across Europe, including the Swiss National Research Council, the EC Presidents Science and Technology Advisory Council, and the EMBO Council, which she chaired.
Iris Rajman, PhD,
Global Head Clinical Pharmacology and profiling Translational Medicine Novartis Pharmaceuticals.
Iris Rajman is also the Site Head for Translational Medicine in Basel.
After gaining her MD, Iris specialized in clinical pharmacology and went on to obtain a PhD in cardiovascular research and lipidology from University of Birmingham, UK. She spent several years working in academia and clinical research at Queen Elizabeth Hospital, Birmingham and St. Thomas’ Hospital, London before moving to Eli Lilly and Company, UK.
Prior to her move to Novartis in Basel, Iris worked in the US at Pfizer. In her current role at Novartis, Iris is responsible for setting clinical development strategy for projects across different therapeutic areas, both in early and late phase drug development.
Dr. Genevieve Almouzni, Director, Research Center Institut Curie, Paris
Geneviève Almouzni aims to develop a continuum from basics science towards medical applications, and promote the junior scientists. From 1999 to 2015, she has been the head of a Research Unit/department (a mixed unit CNRS-Institut Curie) where she developed work on genome organization and function.
Her scientific contribution has been central to define key mechanisms in chromatin assembly from the basic unit, the nucleosome, up to higher order structure in the nucleus. She has exploited various approaches from original biochemistry with in vitro systems and use of single molecules up to imaging analysis and functional studies to characterize nuclear architecture. She addressed these issues during cell cycle, development and in response to DNA damage, with a constant interest for cancer biology. This work received continuous funding support – she is recipient of several international grants (Human Science Frontier, several European grants including ERC Advanced Grant) – and gave rise to over 200 peer-reviewed publications.
She received prestigious awards, i.e. member of the Académie des Sciences (2013), Woman in Sciences FEBS /EMBO (2013), and AAAS Fellow (American Association for the Advancement of Science, 2014). As an active member of several international scientific advisory boards worldwide and also in several editorial board (Cell, EMBO Journal, Genes & Development, etc.), she contributes to the scientific community development. In Europe, this has led her to be appointed as Vice-chair at the EMBO Council in 2014 and Vice-chair of the EU-Life alliance in 2015.
Her major investment in the development of the field of Epigenetics over the years, led her to engage in several EU networks.
Her most recent role as coordinator of EpiGeneSys, a Network of Excellence has enabled to move epigenetics towards quantitative approaches and exploit systems biology strategies and create a unique European community, paving the way for future initiatives.
Prof. Anna Fontcuberta i Morral,
EPFL, Ecole Polytechnique Federale de Lausanne, Physical Science and Engineering, Laboratory of semiconductor Materials.
Prof. Anna Fontcuberta i Morral finished her studies in physics at the University of Barcelona (Spain) in 1997. She obtained her masters in materials science from the University of Paris XI (France) in 1998 and her PhD in materials science from Ecole Polytechnique (France) in 2001.
In 2001 and 2002 she was a postdoctoral fellow at the group of Prof. Harry A. Atwater at the California Institute of Technology. After that she obtained a permanent research position at the French research council (CNRS) at Ecole Polytechnique (France). In 2004, she took a leave of absence to return to the California Institute of Tehcnology, where she co-founded the startup company Aonex Technologies Inc.. Then, in 2005 she started her own research group in the chair of Prof. G. Abstreiter of the Technical University of Munich (Germany). Since 2008 she directs the Laboratory of Semiconductor Materials at the Institute of Materials of the Ecole Polytechnique Fédérale de Lausanne (Switzerland). Her current research interest is the synthesis and nanoscale characterization of semiconductor nanostructures such as nanowires for solar energy conversion.
Caroline Boulton, BPharm, Ph.D,
Global Head Regulatory Affairs, Cardio-metabolic Franchise, Novartis Pharmaceuticals.
Caroline is a highly experienced regulatory affairs professional with a 20 year career in the Innovative Pharmaceuticals Industry. She works currently at Novartis Pharmaceuticals where she leads the Global Regulatory Affairs team within the Cardio-metabolic Franchise. In that role, she is responsible for securing and maintaining Product Licenses for the cardio-metabolic portfolio of products and for developing and supporting a diverse team of regulatory professionals.
Prior to joining Novartis, Caroline worked within Regulatory Affairs at Roche Pharmaceuticals, Amgen and SmithKline Beecham and also set up her own regulatory consultancy business during a career break for childcare. She transitioned into regulatory affairs after working for a number of years as a postdoctoral scientist within research groups in the U.K. and Germany.
Caroline has a PhD in Neuroscience from the University of Manchester, U.K. and a Pharmacy degree from the University of London, U.K.
Suzanne Elvidge, MSc.
Science journalist, featured in publications such as Nature Biotechnology, FierceMarkets, and European Life Science, among many others.
I have been communicating using the written word for the whole of my 25-year career in journalism, feature writing, publishing, communications and PR. I have worked as a freelance writer since 2006, and write about pharmaceuticals, consumer healthcare and medicine, and the healthcare, pharmaceutical and biotechnology industries, for industry, science, healthcare professional and patient audiences.
As a freelancer I have written features, news and company profiles for a range of publications including Nature Biotechnology, FierceMarkets newsletters (FierceDrugDelivery, FierceBiomarkers, Fierce BiotechResearch and FierceVaccines), Nature Reviews Drug Discovery, Nature BioPharma Dealmakers, Life Science Leader, Start Up, New Scientist, European Life Science, Drug Discovery Today, New Pharma Magazine (now New Pharma Thinkers), Observe, and Chemistry & Industry, as well as in-depth reports and e-books on a range of industry topics for FirstWord, Datamonitor, and FierceMarkets.
I have written disease area reports based on meetings, interviews and desk research. I have worked on communications programs for pharma companies, including writing presentations, slide kits, fliers, brochures and marketing emails, developing messaging and creating and updating value and submission dossiers. I have also created and edited press releases, web pages and marketing materials, and have written healthcare, lifestyle and science articles for consumer websites. Areas of scientific focus include small molecule and biologic therapeutics, genomics and big data. Areas of clinical focus include: oncology, respiratory medicine, musculoskeletal disorders, neurologic and psychiatric disorders and gastrointestinal disease, amongst others. I am active on Twitter and blog on scientific, business and consumer sites, writing on topics from PCR, through bioinformatics and big data, to interesting and quirky science facts, books and food.
My first degree is in biochemistry and pharmacology, and I have an MSc from the Open University.
I am based in the Derbyshire Peak District, where I live above and co-own a second-hand bookshop. I have developed and taught courses and presented at conferences on various health, social care and biopharma business topics, on writing and editing skills, and on science in the media. I am also a published fiction writer and poet and amateur actor.